US20120232040A1

US20120232040A1 - Medication for clinical extensively-drug resistant acinetobacter baumannii

Info

Publication number: US20120232040A1
Application number: US13/042,065
Authority: US
Inventors: Yen-Hsu Chen; Hui-Min Wang; Chung-Yi Chen; Hsi-An Chen; Wei-Ru Lin
Original assignee: Kaohsiung Medical University
Current assignee: Kaohsiung Medical University
Priority date: 2011-03-07
Filing date: 2011-03-07
Publication date: 2012-09-13
Also published as: US20140018324A1; US8802737B2

Abstract

A medication for Acinetobacter baumannii infection comprises tetracycline; and a ginger compound, selecting from a group of [6]-dehydrogingerdione, [10]-gingerol, [6]-shogaol and [6]-gingerol. Also, a method for improving tetracycline-resistance of A. baumannii, by providing the ginger compound described above combined with tetracycline to against A. baumannii infection.

Description

BACKGROUND OF THE INVENTION

1. Field of the Invention
The present invention relates to a medication for bacterial infection particularly to a medication for extensively drug resistant Acinetobacter baumannii.
2. Description of the Related Art
Acinetobacter baumannii, as referred to a non-enteric gram-negative bacillus, is a common pathogenic bacterium generally leading to severe pneumonia, sepsis, and various infections on urinary tract and respiratory tract. Since 1980s, an increasing amount of antibiotics has been used on A. baumannii infection. The A. baumannii tends to show multiple drug-resistance to most commercial antibiotics, including penicillins, cephalosporins, monobactam, aminoglycosides, carbapenems, sulbactam and fluroroquinolones. Accordingly, drug resistant A. baumannii has becomes a major cause of nosocomal infection, and which always results in serious mortality, especially in intensive care units due to the lack of proper antimicrobials.
In recent decades, since the drug-resistance getting controversial, natural components and plant extracts have reported to play an important role in antimicrobial approaches. Referring to U.S. Pat. No. 6,264,926, entitled with “FORMULATION USEFUL AS A NATURAL HERBAL TOOTH POWDER” a formulation of herbal toothpowder or toothpaste for gums and teeth is disclosed and comprises powder or paste of Zingiber officinale, Zanthoxylum armaatum, Santalum album, Spilanthes calva, Pistacia lentiseus, Quercus infectoria, Usnea longissima, roasted alum and common salt. It is suggested that ginger has generally antimicrobial and anti-inflammatory effects, and which can be used as a general antimicrobial ingredient in various products. However, the conventional invention only points out a general antimicrobial effect of the ginger rather than a specific antimicrobial function on particular pathogen.
With reference to Taiwan Published Patent No. 200918085, entitled with “USE OF A POTENT PRODUCT EXTRACTED FROM RHIZOMES OF ZINGIBER OFFICINALE IN TREATING A DISEASE ASSOCIATED WITH HELICOBACTER PYLORI” a new medical composition treated of Helicobacter pylori is provided and comprises a crude extract from rhizomes of Zingiber officinale. It is suggested that with a potent fraction obtained via fractionated steps disclosed in the TW Patent No. 200918085, a disease associated with H. pylori, such as gastritis, gastric ulcer and duodenal ulcer can be effectively treated. However, the conventional invention above is useless in clinical drug-resistant problem, also in severe nosocomial infection of Acinetobacter baumannii. Hence, there is a pressing need of providing a new medication, as well as a new therapeutic approach for the extensive drug-resistant Acinetobacter baumannii worldwide.

SUMMARY OF THE INVENTION

The primary objective of this invention is to provide a medication for Acinetobacter baumannii infection, which can treat of clinical extensively drug-resistant Acinetobacter baumannii infection.
The secondary objective of this invention is to provide a medication for Acinetobacter baumannii infection, so as to prevent from nosocomial infection of Acinetobacter baumannii.
Another objective of this invention is to provide a method for improving tetracycline-resistance of Acinetobacter baumannii, which can improve serious drug-resistant issue in clinical medicine.
Another objective of this invention is to provide a method for improving tetracycline-resistance of Acinetobacter baumannii, so as to effectively inhibit clinical A. baumannii infection and prevent from nosocomial infection.
A medication for Acinetobacter baumannii infection, comprises tetracycline; and a ginger compound, selecting from a group of [6]-dehydrogingerdione, [10]-gingerol, [6]-shogaol and [6]-gingerol.
A method for improving tetracycline-resistance of Acinetobacter baumannii, by providing the ginger compound described above combined with tetracycline to against A. baumannii infection.
Further scope of the applicability of the present invention will become apparent from the detailed description given hereinafter. However, it should be understood that the detailed description and specific examples, while indicating preferable embodiments of the invention, are given by way of illustration only, since various more will become apparent to those skilled in the art from this detailed description.

BRIEF DESCRIPTION OF THE DRAWINGS

The present invention will become more fully understood from the detailed description given herein below and the accompanying drawings which are given by way of illustration only, and thus are not limitative of the present invention, and wherein:

FIG. 1 is a diagram illustrating the structure of [6]-shogaol in the present invention;

FIG. 2 is a diagram illustrating the structure of [6]-dehydrogingerdione in the present invention;

FIG. 3 is a diagram illustrating the structure of [6]-gingerol in the present invention;

FIG. 4 is a diagram illustrating the structure of [10]-gingerol in the present invention.

All figures are drawn for ease of explaining the basic teachings of the present invention only; the extensions of the figures with respect to number, position, relationship, and dimensions of the parts to form the preferred embodiment will be explained or will be within the skill of the art after the following teachings of the present invention have been read and understood. Further, the exact dimensions and dimensional proportions conforming to specific force, weight, strength, and similar requirements will likewise be within the skill of the art after the following teachings of the present invention have been read and understood.

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to a medication for Acinetobacter baumannii infection comprising tetracycline and a ginger compound, such as [6]-shogaol, [6]-dehydrogingerdione, [6]-gingerol, and [10]-gingerol. The medication for Acinetobacter baumannii infection can significantly suppress A. baumannii infection, especially to extensively drug-resistant Acinetobacter baumannii infection. With such medication, the severe nosocomial infection of Acinetobacter baumannii can be effectively reduced.
In the present invention, the ginger compound is prepared and mixed with 25 m/ml of tetracycline, wherein the ginger compound can be one of [6]-shogaol, [6]-dehydrogingerdione, [6]-gingerol, [10]-gingerol, and their composition. In the present embodiment, the ginger compound is extracted from dried and chipped rhizomes of Zingiber officinale with a mixture of CHCl₃-MeOH at room temperature, according to a method published by Chen et al. in 2009. With such performance, an extraction is obtained, and further fractionated by silica gel column chromatography with gradients of n-hexane/CHCl₃, in order to collect the [6]-shogaol, [6]-dehydrogingerdione, [6]-gingerol, and [10]-gingerol of the present invention. Referring to FIGS. 1 to 4, the structures of the [6]-shogaol, [6]-dehydrogingerdione, [6]-gingerol, and [10]-gingerol are shown respectively. In the present invention, the obtained [6]-shogaol, [6]-dehydrogingerdione, [6]-gingerol, and [10]-gingerol are further analyzed by spectroscopy and stored in DMSO as a concentration of 10 mM till being used.
For further proving the efficiency of the medication in the present invention, various strains of clinical A. baumannii, being extensively drug-resistant, are randomly isolated from numbers of patients suffered from severe nosocomal infections of A. baumannii for a medication test of the present invention. Precisely, five strains of clinical A. baumannii, named AB1, AB2, AB4, AB5, AB6, are isolated from patients in Kaohsiung Medical University Hospital, 1600-bed tertiary referral medical center in Taiwan, wherein each of strains is from different clones by genotyping and collected from different samples, for example, sputum, wound pus, blood, pleural fluid, and bronchial washing. All of the five strains of A. baumannii are stored in trypticase soy broth (Difco Laboratories, Detroit, Mich.) with 20% glycerol at −80° C. until the following use.
With reference to TABLE 1, the susceptibility values of the five strains of A. baumannii to various commercial antibiotics are shown. In the present invention, the minimal inhibitory concentration (MIC) of each commercial antibiotic is determined respectively on each strain of A. baumannii via a broth micro-dilution method with LB broth reported by Nariman et al. in 2004. Since the drug-resistance standards for A. baumannii recommended by the Clinical and Laboratory Standards Institute (CLSI, 2009) are summarized in that: ampicillin/sulbactam≧32/16 μg/mL, cefepime≧32 μg/mL, ceftazidime≧32 μg/mL, ceftriaxone≧64 μg/mL, gentamicin≧16 μg/mL, meropenem≧16 μg/mL, piperacillin≧128 μg/mL, tetracycline≧16 μg/mL, trimethoprim/sulfamethoxazole≧4/76 μg/mL, it suggests all of the five strains of A. baumannii share significant and extensive drug-resistance to all of the commercial antibiotics. Some of the antibiotics including ampicillin, cefazolin and cefmetazole have no MIC breakpoints according to CLSI.

TABLE 1

susceptibilities of the five strains of A. baumannii to antibiotics
(MICs, μg/ml)

Strains

Antibiotics	AB1	AB2	AB4	AB5	AB6

Ampicillin	≧512	≧512	≧512	≧512	≧512
Ampicillin/	≧32/16	≧32/16	≧32/16	≧32/16	≧32/16
Sulbactam
Cefazolin	≧64	≧64	≧64	≧64	≧64
Cefepime	≧64	≧64	≧64	≧64	≧64
Cefmetazole	≧64	≧64	≧64	≧64	≧64
Ceftazidime	≧64	≧64	≧64	≧64	≧64
Ceftriaxone	≧64	≧64	≧64	≧64	≧64
Gentamicin	≧16	≧16	≧16	≧16	≧16
Meropenem	≧16	≧16	≧16	≧16	≧16
Piperacillin	≧128	≧128	≧128	≧128	≧128
Piperacillin/	≧128	≧128	≧128	≧128	≧128
Tazobactam
Tetracycline	32	≧512	≧512	≧512	≧512
Trimethoprim/	≧16/	≧16/	≧16/320	≧16/320	≧16/320
Sulfamethoxazole	320	320

In the present embodiment, 10⁵cfu/mL of each strain of A. baumannii are prepared, and the medication test of the present invention is carried out by respectively providing the medication of the present invention and the ginger compound only to each strain of A. baumannii. In this way, the antimicrobial activities of the medication of the present invention and of the ginger compound only are monitored and recorded respectively. Precisely, the medication test of the present invention has 4 steps, including (a) [6]-shogaol step, (b) [6]-dehydrogingerdione step, (c) [6]-gingerol step, and (d) [10]-gingerol step, in order to separately analyze the antimicrobial activities of the medication with various formula of 25 μg/mL tetracycline and [6]-shogaol, 25 μg/mL tetracycline and [6]-dehydrogingerdione, 25 μg/mL tetracycline and [6]-gingerol, also 25 μg/mL tetracycline and [10]-gingerol individually.
Referring to TABLE 2, the MIC values of the medication with 25 μg/mL tetracycline and [6]-shogaol against the five strains of A. baumannii are summarized. It is suggested that the medication of the present invention, consisting of 25 μg/mL tetracycline and [6]-shogaol, shows significant antimicrobial effect against to all of the five strains of A. baumannii. Furthermore, the [6]-shogaol itself also has dramatically antimicrobial ability to the five strains of A. baumannii, with diverse MIC values from 208.1 μM to 347.2 μM on different strains of A. baumannii.

TABLE 2

antimicrobial activities of the medication (a)

	[6]-shogaol	Medication
groups	only (μM)	(Tetracycline + [6]-shogaol) (μM)

AB1	208.1	<10.0
AB2	274.0	<10.0
AB4	279.7	<10.0
AB5	261.3	<10.0
AB6	347.2	<10.0

Referring to TABLE 3, the MIC values of the medication with 25 μg/mL tetracycline and [6]-dehydrogingerdione against the five strains of A. baumannii are summarized. It is suggested that the medication of the present invention, consisting of 25 μg/mL tetracycline and [6]-dehydrogingerdione, shows significant antimicrobial effect against to all of the five strains of A. baumannii. Furthermore, the [6]-dehydrogingerdione itself also has dramatically antimicrobial ability to the five strains of A. baumannii, with diverse MIC values from 137.6 μM to 207.1 μM on different strains of A. baumannii.

TABLE 3

antimicrobial activities of the medication (b)

		Medication
	[6]-dehydrogingerdion	(tetracycline + [6]-dehydrogingerdion)
groups	only (μm)	(μg/μM)

AB1	198.1	<10.0
AB2	166.2	<10.0
AB4	137.6	<10.0
AB5	178.5	<10.0
AB6	207.1	<10.0

Referring to TABLE 4, the MIC values of the medication with 25 μg/mL tetracycline and [6]-gingerol against the five strains of A. baumannii are summarized. It is suggested that the medication of the present invention, consisting of 25 μg/mL tetracycline and [6]-gingerol, shows significant antimicrobial effect against to all of the five strains of A. baumannii. Furthermore, the [6]-gingerol itself also has dramatically antimicrobial ability to the five strains of A. baumannii, with diverse MIC values from 226.4 μM to 277.3 μM on different strains of A. baumannii.

TABLE 4

antimicrobial activities of the medication (c)

	[6]-gingerol	Medication
groups	only (μM)	(tetracycline + [6]-gingerol) (μg/μM)

AB1	226.4	<10.0
AB2	226.8	<10.0
AB4	297.1	<10.0
AB5	277.3	<10.0
AB6	275.6	<10.0

Referring to TABLE 4, the MIC values of the medication with 25 μg/mL tetracycline and [10]-gingerol against the five strains of A. baumannii are summarized. It is suggested that the medication of the present invention, consisting of 25 μg/mL tetracycline and [10]-gingerol, shows significant antimicrobial effect against to all of the five strains of A. baumannii. Furthermore, the [10]-gingerol itself also has dramatically antimicrobial ability to the five strains of A. baumannii, with diverse MIC values from 196.0 μM to 207.5 μM on different strains of A. baumannii.

TABLE 5

antimicrobial activities of the medication (d)

	[10]-gingerol	Medication
groups	only (μM)	(tetracycline + [10]-gingerol) (μg/μM)

AB1	144.6	<10.0
AB2	162.3	<10.0
AB4	196.0	<10.0
AB5	207.5	<10.0
AB6	198.1	<10.0

In summary, the ginger compound of the present invention shows dramatically inhibition on all of the five strains of A. baumannii, with diverse MIC values from 132 μM to 347 μM. With the combination of the ginger compound of the present invention and tetracycline, tetracycline-resistance of the five strains of A. baumannii as it is listed in TABLE 1 can be dramatically improved. Accordingly, antimicrobial activities of ginger compound of the present invention with 25 μg/mL tetracycline are significantly effective against to A. baumannii infection. In the present invention the ginger compound is at a concentration of higher than 0 μM and lower than 10 μM.
Through the present invention, a medication compromising 25 μg/ml tetracycline and the ginger compound of the present invention is provided, wherein the ginger compound is selected from a group of [6]-shogaol, [6]-dehydrogingerdione, [6]-gingerol and [10]-gingerol, with a MIC value of <10 μM. The medication of the present invention is sufficient to suppress A. baumannii clinical infection, even for extensively drug-resistant A. baumannii, so that the medication of the present invention can prevent from clinical nosocomial infection of A. baumannii. The medication of the present invention can be manufactured into any form including a tablet, liquid powder or infection and preferable for the form of solution. In general, the medication of the present invention can be given individually or combined with other acceptable medicaments to patients suffered from severe A. baumannii infection, with the ginger compound at a preferable concentration of lower than 10 μM and higher than 0 μM.
Additionally, a new therapeutic approach for improving tetracycline-resistance of clinical A. baumannii strains is also developed by providing ginger compound of the present invention combined with tetracycline to against to A. baumannii infection. Preferably, the ginger compound of the present invention can be one of [6]-shogaol, [6]-dehydrogingerdione, [6]-gingerol, [10]-gingerol and their composition. Preferably, the tetracycline is at a concentration of 25 μg/ml and combines with one of [6]-shogaol, [6]-dehydrogingerdione, [6]-gingerol, [10]-gingerol and their composition at a concentration of lower than 10 μM and higher than 0 μM. With such approach, severe clinical A. baumannii infections, especially for extensively drug-resistant A. baumannii infections can be effectively controlled.
Although the invention has been described in detail with reference to its presently preferred embodiment, it will be understood by one of ordinary skill in the art that various modifications can be made without departing from the spirit and the scope of the invention, as set forth in the appended claims.

Claims

1. A medication for Acinetobacter baumannii infection, comprising:

tetracycline; and

a ginger compound selected from a group of [6]-dehydrogingerdione, [10]-gingerol, [6]-shogaol and [6]-gingerol.

2. The medication for Acinetobacter baumannii infection as defined in claim 1, with the tetracycline at a concentration of 25 μg/ml.

3. The medication for Acinetobacter baumannii infection as defined in claim 1, with the ginger compound at a concentration of lower than 10 μM and higher than 0 μM.

4. A method for improving tetracycline-resistance of Acinetobacter baumannii, by providing the ginger compound as defined in claim 1 combined with tetracycline to against A. baumannii infection.

5. The method for improving tetracycline-resistance of Acinetobacter baumannii as defined in claim 4, wherein the ginger compound is at a concentration of lower than 10 μM and higher than 0 μM.

6. The method for improving tetracycline-resistance of Acinetobacter baumannii as defined in claim 4, with the tetracycline at a concentration of 25 μg/ml.